FutureChem Completes U.S. Clinical Trial Enrollment for Novel Prostate Cancer Treatment
[CITY, STATE] – FutureChem, a radiopharmaceutical company, announced today the successful completion of patient enrollment in its U.S.clinical trial evaluating FC705 for metastatic castration-resistant prostate cancer (mCRPC). The trial, initiated in May 2024, enrolled 20 patients across six hospitals, including the University of Maryland Medical Center, and concluded enrollment approximately 15 months later.
Prostate cancer is the most commonly diagnosed cancer in men in the United States, wiht roughly 270,000 new cases annually. mCRPC represents the most advanced stage of the disease, characterized by resistance to standard hormone therapies.
FutureChem anticipates FC705 will demonstrate a strong therapeutic effect with minimized side effects, utilizing half the dosage compared to competing treatments. The company expects U.S. trial results to mirror positive outcomes observed in prior Korean clinical trials. Data analysis will be conducted by a U.S.-based contract research association (CRO) following the completion of final patient observation periods.
According to FutureChem officials, the effectiveness of radiopharmaceuticals hinges on rapid initial tumor uptake and sustained retention. The company highlights FC705’s leading intake rate (%ID/G) among prostate cancer drugs in development, increasing the potential for technology transfer agreements with global pharmaceutical firms.
The radiopharmaceutical treatment (RPT) market for prostate cancer is experiencing ample growth, extending beyond tertiary treatment options to include secondary and primary care settings. Novartis’ Pluvicto generated $1.39 billion in revenue last year and $830 million in the first half of this year.
FutureChem is preparing to submit an submission for Phase 3 clinical approval and conditional authorization for FC705.
